protein

Cytokeratin 19, CK19 Protein (Active)

MBS355584

0.1 mg

510 USD

Recombinant Protein

Cytokeratin 19, CK19 Protein (Active)

Cytokeratin 19, CK19

Keratin type I cytoskeletal 19; Cytokeratin-19; CK-19; Keratin-19; K19; KRT19; CK19

CK19

E Coli

>95% by SDS-PAGE

Liquid

1 mg/ml

Ship at 4 degree C. Upon receipt, aliquot and store at -20 degree C or -80 degree C for long term. Avoid repeated freeze and thaw cycles.

ELISA (EIA), SDS-PAGE

Storage Buffer: Each vial contains Tris-HCl (pH7.4 +/- 0.2) with 0.2% sodium azide

Recombinant full length human Cytokeratin 19 protein with molecular weight 40 kDa. Cytokeratin 19 (CK19) belongs to a family of keratins, which are normally expressed in the lining of the gastroenteropancreatic and hepatobiliary tracts. It has been shown to be an independent prognostic factor for pancreatic neuroendocrine tumors, especially the insulin-negative tumors. CK19 positive tumors are associated with poor outcome irrespective of the established pathologic parameters such as size, mitoses, lymphovascular invasion, and necrosis. The low-molecular-weight cytokeratin (CK) protein CK19 has been shown to have diagnostic use and prognostic significance in some types of human malignancy. Cytokeratin-19 alone and its combinations with other markers were more sensitive in accurate diagnosis of papillary carcinoma than the other combinations.

1. Jain R, Fischer S, Serra S, Chetty R. The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol. 2010; 18(1):9-15. 2. Stewart CJ, Crook ML, Lacey J, Louwen K. Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium. Int J Gynecol Pathol. 2011; 30(5):484-91. 3. Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol. 2010; 21(2):80-9.

0.1 mg

510 USD